cobra venom factor cvf  (TargetMol)

Journal: Bioactive Materials

Article Title: Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy

doi: 10.1016/j.bioactmat.2026.02.018

Figure Lengend Snippet: In vivo splenic DC-specific transfection of mRNA/H 18 NPs and in vitro protein corona analysis of mRNA/H 18 NPs. (A) EGFP protein expression in splenic cell subsets of C57BL/6J mice 24 h post intravenous injection of different formulations. (B) The top 5 most abundant plasma proteins adsorbed on mRNA/H 18 NPs (C3: Complement C3; Ighm: Immunoglobulin heavy constant mu; Hbat1: Alpha-globin; Itih4: Inter alpha-trypsin inhibitor, heavy chain 4; Cnn2: Calponin). (C) Heatmap plot of major proteins in the protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. PBS group was used as a negative control. (D) Quantification of major adsorbed protein categories of different formulations. (E) Complement C3 abundance in protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. (F) Bioluminescence images of major organs and (G) Quantification of total bioluminescence flux in the spleen from C57BL/6J mice 6 h after intravenous injection of mLuc/H 18 NPs (mLuc dose of 0.25 mg kg −1 ). Mice were pre-treated with cobra venom factor (CVF) or PBS. (H) Fluorescence quantification of Cy5 mRNA delivered by uncoated or complement C3-coated Cy5-mRNA/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. (I) Bioluminescence intensity of luciferase protein translated from mRNA delivered by uncoated or complement C3-coated mLuc/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. Data were shown as mean ± SD (n = 3).

Article Snippet: Cobra venom factor (CVF) was purchased from TargetMol (MA, USA).

Techniques: In Vivo, Transfection, In Vitro, Expressing, Injection, Clinical Proteomics, Negative Control, Combined Bisulfite Restriction Analysis Assay, Fluorescence, Incubation, Blocking Assay, Luciferase

Journal: bioRxiv

Article Title: Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes

doi: 10.64898/2026.03.16.712023

Figure Lengend Snippet: (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and Cobra venom factor (CVF) treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.

Article Snippet: Prior to Listeria opsonization, human serum was de-complemented using 12 μg of cobra venom factor (CVF) (Quidel, San Diego, USA) per 500 μl of extracted serum and incubated for 1 h at 37 °C ( ).

Techniques: Labeling, Comparison, Isolation, Infection, Blocking Assay, Combined Bisulfite Restriction Analysis Assay, Control